Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS‐CoV‐2 Infection in Older Adults During the JN.1 Lineage‐Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023–1 March 2024Lore Merdrignac, Noémie Sève, Camino Trobajo‐Sanmartín et al.|Influenza and Other Respiratory Viruses|2024Cited by 14
Effectiveness of XBB.1.5 Vaccines against Symptomatic SARS-CoV-2 Infection in Older Adults during the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023–1 March 2024Lore Merdrignac, Esther Kissling, Charlotte Lanièce Delaunay et al.|SSRN Electronic Journal|2024Cited by 1
Effectiveness of XBB.1.5 vaccines against symptomatic SARS-CoV-2 infection in older adults during the JN.1 lineage-predominant period, European VEBIS primary care multicentre study, 20 November 2023--1 March 2024Lore Merdrignac, Esther Kissling, Charlotte Lanièce Delaunay et al.|Unknown|2024Cited by 0